Pasireotide (ditrifluoroacetate)

Hersteller MedChem Express
Typ Inhibitors
Specific against other
Menge 5mg
ArtNr HY-79135-5mg
eClass 6.1 30220300
eClass 9.0 32160605
SOM230 ditrifluoroacetate, Pasireotide TFA salt
10 mM in DMSO
Biological Description
Pasireotide (ditrifluoroacetate) is a stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively).
IC50 & Target: pKi: 8.2 (sst1), 9.0 (sst2), 9.1 (sst3), <7.0 (sst4), 9.9 (sst5)
In Vitro: Pasireotide effectively inhibits the growth hormone releasing hormone (GHRH) induced growth hormone (GH) release in primary cultures of rat pituitary cells with an IC50 of 0.4+/-0.1 nM[1].
In Vivo: Pasireotide potently suppressess GH secretion in rats. The ED50 values determined at 1 and 6 h after injection of pasireotide indicates its very long duration of action in vivo. In the rat, pasireotide strongly decreases IGF-1 plasma levels, with the efficacy being markedly enhanced compared with the effects elicited by SMS 201-995 after 7 days of treatment. Furthermore, in rats, dogs, and rhesus monkeys, pasireotide potently and dose-dependently decreases IGF-1 levels for prolonged periods of time without desensitization[1]. Pasireotide (160 mg/kg/month, s.c.) decreases serum insulin levels and increases serum glucose levels, reduces PNET tumor size, and demonstrates a reduction in tumor activity on PET/CT scan in Pdx1-Cre; Men1 floxed/floxed conditional knockout mice[2]. Pasireotide (50 ug/kg) inhibits arthritic joint swelling in a dose-dependent manner, strongly inhibits joint swelling during the acute phase of AIA. Pasireotide- and octreotide-treated mice show significantly increased mechanical thresholds on the inflamed side. Pasireotide potently decreases secondary hyperalgesia to mechanical and thermal stimuli. Mechanical thresholds in the pasireotide-treated mice are significantly higher than those in the saline-treated or octreotide-treated animals[3].
Lorenzo Pisarello M, et al. The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease . Am J Pathol. 2018 Jan 20. pii: S0002-9440(17)30796-4.
Menge: 5mg
Lieferbar: In stock
Listenpreis: 723,93 €
Preis: 723,93 €


Angebot anfordern

Fragen zum Produkt?